DNA cross-link repair 1C pseudogene 1Genealiases: []
Q-omics provides the consensus-scored DCLRE1CP1 profile across patient tissues and cancer cell-line models. DCLRE1CP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DCLRE1CP1 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, DCLRE1CP1 RNA expression shows 9,064 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUAD, and TGCT as cancer lineages where DCLRE1CP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCLRE1CP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCLRE1CP1 survival associations across molecular data types. DCLRE1CP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCLRE1CP1 RNA expression–survival associations across cancer types. High DCLRE1CP1 expression shows unfavorable associations in UVM, but favorable associations in BLCA, SKCM, HNSC, LUAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DCLRE1CP1 RNA expression.
This table summarizes DCLRE1CP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for DCLRE1CP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCLRE1CP1 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, THCA, STAD and KIRP. The LUAD box plot shows higher DCLRE1CP1 RNA expression in normal versus tumor tissue (log2 FC = −1.158, t-test p < 0.001).
This table shows molecular features associated with DCLRE1CP1 in patient tissues and cancer cell lines. In patient samples, DCLRE1CP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
